NAS:XON (USA) Also trade in: Germany

Intrexon Corp

$ 4.69 0 (0%)
Volume: 1,258,514 Avg Vol (1m): 2,986,641
Market Cap $: 753.99 Mil Enterprise Value $: 808.79 Mil
P/E (TTM): 0.00 P/B: 2.25
Earnings Power Value -14.68
Net Current Asset Value -1.08
Tangible Book 0.24
Projected FCF -4.68
Median P/S Value 15.38
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.85
Cash-To-Debt ranked lower than
55.29% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
XON: 0.85
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.85, Med: 24.42, Max: 124.89
Current: 0.85
0.85
124.89
Equity-to-Asset 0.44
Equity-to-Asset ranked lower than
58.06% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
XON: 0.44
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -2.12, Med: 0.61, Max: 0.8
Current: 0.44
-2.12
0.8
Debt-to-Equity 0.69
Debt-to-Equity ranked higher than
88.20% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
XON: 0.69
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -0.01, Med: 0.02, Max: 0.69
Current: 0.69
-0.01
0.69
Debt-to-EBITDA -0.43
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
XON: -0.43
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -0.43, Med: -0.07, Max: 0
Current: -0.43
-0.43
0
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -3.53
DISTRESS
GREY
SAFE
Beneish M-Score -4.91
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -100.17%
WACC 13.04%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -312.87
Operating Margin ranked higher than
56.57% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
XON: -312.87
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -1028.67, Med: -170.73, Max: -52.44
Current: -312.87
-1028.67
-52.44
Net Margin % -363.19
Net Margin ranked higher than
57.07% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
XON: -363.19
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -1064.27, Med: -138.91, Max: -48.67
Current: -363.19
-1064.27
-48.67
ROE % -113.00
ROE ranked higher than
61.88% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
XON: -113
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -254.03, Med: -25.77, Max: -15.66
Current: -113
-254.03
-15.66
ROA % -63.47
ROA ranked higher than
67.53% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
XON: -63.47
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -74.27, Med: -17.49, Max: -10.84
Current: -63.47
-74.27
-10.84
ROC (Joel Greenblatt) % -486.31
ROC (Joel Greenblatt) ranked higher than
63.80% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
XON: -486.31
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -491.84, Med: -345.87, Max: -161.15
Current: -486.31
-491.84
-161.15
3-Year Total Revenue Growth Rate -2.60
3-Year Revenue Growth Rate ranked higher than
85.10% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
XON: -7.4
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -20, Med: -7.4, Max: 40.8
Current: -7.4
-20
40.8
3-Year Total EBITDA Growth Rate -93.80
3-Year EBITDA Growth Rate ranked lower than
58.73% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
XON: -84.1
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -84.1, Med: -2.7, Max: 64.2
Current: -84.1
-84.1
64.2
3-Year EPS w/o NRI Growth Rate -72.90
3-Year EPS w/o NRI Growth Rate ranked lower than
62.25% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
XON: -72.9
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
N/A

» XON's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:XON

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 541714    SIC : 8731
Compare SZSE:300147 NAS:ZIOP NAS:PRNB SZSE:300363 LSE:PRTC OSTO:BIOA B XPAR:DBV OTCPK:MRMD NAS:ARVN NAS:NTLA NAS:AKBA NAS:ITCI NAS:GTHX SHSE:600200 OSTO:KARO TSE:4563 SZSE:300497 NAS:ATNX NAS:URGN OCSE:BAVA
Traded in other countries I5X.Germany
Address 20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876
Intrexon is a biotechnology company that develops synthetic biology solutions. The company designs, builds, and regulates gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Ratios

Current vs industry vs history
PB Ratio 2.25
PB Ratio ranked higher than
55.93% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
XON: 2.25
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.01, Med: 4.99, Max: 14.93
Current: 2.25
2.01
14.93
PS Ratio 4.35
PS Ratio ranked higher than
57.71% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
XON: 4.35
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 3.8, Med: 14.22, Max: 66.82
Current: 4.35
3.8
66.82
EV-to-EBIT -1.51
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
XON: -1.51
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -3216.9, Med: -16.65, Max: -1.3
Current: -1.51
-3216.9
-1.3
EV-to-EBITDA -1.59
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
XON: -1.59
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -281.9, Med: -18.95, Max: 420.3
Current: -1.59
-281.9
420.3
EV-to-Revenue 5.61
EV-to-Revenue ranked higher than
58.50% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
XON: 5.61
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 4.7, Med: 16.3, Max: 136.8
Current: 5.61
4.7
136.8
Current Ratio 3.91
Current Ratio ranked lower than
73.84% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
XON: 3.91
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.81, Med: 3.68, Max: 10.49
Current: 3.91
0.81
10.49
Quick Ratio 3.57
Quick Ratio ranked lower than
72.91% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
XON: 3.57
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.81, Med: 3.36, Max: 10.49
Current: 3.57
0.81
10.49
Days Inventory 115.20
Days Inventory ranked higher than
55.51% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
XON: 115.2
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 115.2, Med: 141.24, Max: 244.37
Current: 115.2
115.2
244.37
Days Sales Outstanding 50.25
Days Sales Outstanding ranked higher than
79.04% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
XON: 50.25
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 0.91, Med: 36.31, Max: 73.99
Current: 50.25
0.91
73.99
Days Payable 72.60
Days Payable ranked lower than
61.38% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
XON: 72.6
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 28.36, Med: 63.99, Max: 17536.59
Current: 72.6
28.36
17536.59

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -3.50
3-Year Share Buyback Rate ranked higher than
71.06% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
XON: -3.5
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -176.2, Med: -6.9, Max: -3.5
Current: -3.5
-176.2
-3.5

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 19.54
Price-to-Tangible-Book ranked lower than
77.63% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
XON: 19.54
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 6.83, Med: 12.38, Max: 27.38
Current: 19.54
6.83
27.38
Price-to-Median-PS-Value 0.30
Price-to-Median-PS-Value ranked higher than
76.11% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
XON: 0.3
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.29, Med: 1.04, Max: 4.44
Current: 0.3
0.29
4.44
Earnings Yield (Joel Greenblatt) % -65.92
Earnings Yield (Greenblatt) ranked higher than
51.25% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
XON: -65.92
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -78.2, Med: -6.1, Max: -0.1
Current: -65.92
-78.2
-0.1

More Statistics

Revenue (TTM) (Mil) $ 144.24
EPS (TTM) $ -3.94
Beta 1.91
Volatility % 62.92
52-Week Range $ 3.95 - 19.94
Shares Outstanding (Mil) 160.76

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N